Elevated Lp(a) in 20,000 Patients Raises Stroke Risk
SkimNews Take
The prevalence of inherited high Lipoprotein(a) suggests that a significant portion of the population currently deemed "low risk" by standard cholesterol panels may actually face elevated cardiovascular threats.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers analyzed plasma samples from 20,070 adults aged 40+ from the ACCORD, PEACE, and SPRINT NIH trials, measuring Lp(a) with a standardized assay.
- Elevated Lp(a) (≥175 nmo/L) was linked to a significantly higher incidence of stroke, cardiovascular death, and major adverse cardiovascular events during a median 3.98‑year follow‑up, even among patients on standard cholesterol therapy.
- One in five people worldwide are estimated to have high Lp(a) levels, yet most are unaware because the condition is asymptomatic and not reflected in routine cholesterol tests.
- The study was presented at the 2026 SCAI Scientific Sessions and the CAIC‑ACCI Summit in Montreal, prompting calls for more aggressive risk‑factor management in patients with elevated Lp(a).
Why it matters: One in five patients have elevated Lp(a), a hidden risk that clinicians can now detect with a simple blood test, enabling more aggressive treatment and lowering costly cardiovascular events.
